These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Explaining high alloreactivity as a quantitative consequence of affinity-driven thymocyte selection. Detours V; Perelson AS Proc Natl Acad Sci U S A; 1999 Apr; 96(9):5153-8. PubMed ID: 10220434 [TBL] [Abstract][Full Text] [Related]
5. Alloreactivity: allogeneic presentation of endogenous peptide or direct recognition of MHC polymorphism? A review. Eckels DD Tissue Antigens; 1990 Feb; 35(2):49-55. PubMed ID: 2188395 [No Abstract] [Full Text] [Related]
6. [Mechanisms of allogenic recognition in transplantation systems]. Fedoseeva EV Biokhimiia; 1995 Feb; 60(2):238-49. PubMed ID: 7718667 [TBL] [Abstract][Full Text] [Related]
9. Antigen presentation on MHC molecules as a diversity filter that enhances immune efficacy. van den Berg HA; Rand DA J Theor Biol; 2003 Sep; 224(2):249-67. PubMed ID: 12927531 [TBL] [Abstract][Full Text] [Related]
10. Analysis of specificity for antigen, Mls, and allogenic MHC by transfer of T-cell receptor alpha- and beta-chain genes. Kaye J; Hedrick SM Nature; 1988 Dec; 336(6199):580-3. PubMed ID: 2849059 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and tolerogenicity of self-major histocompatibility complex peptides. Benichou G; Takizawa PA; Ho PT; Killion CC; Olson CA; McMillan M; Sercarz EE J Exp Med; 1990 Nov; 172(5):1341-6. PubMed ID: 1700053 [TBL] [Abstract][Full Text] [Related]
12. Immunology and the challenge of transplantation. Alonso Arias R; López-Vázquez A; López-Larrea C Adv Exp Med Biol; 2012; 741():27-43. PubMed ID: 22457101 [TBL] [Abstract][Full Text] [Related]
13. The paradox of alloreactivity and self MHC restriction: quantitative analysis and statistics. Detours V; Perelson AS Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8479-83. PubMed ID: 10900009 [TBL] [Abstract][Full Text] [Related]
15. Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus. Fedoseyeva EV; Tam RC; Orr PL; Garovoy MR; Benichou G J Exp Med; 1995 Nov; 182(5):1481-91. PubMed ID: 7595218 [TBL] [Abstract][Full Text] [Related]
17. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. Benichou G; Takizawa PA; Olson CA; McMillan M; Sercarz EE J Exp Med; 1992 Jan; 175(1):305-8. PubMed ID: 1730925 [TBL] [Abstract][Full Text] [Related]
18. Indirect recognition of allo MHC peptides--potential role in human transplantation. Watschinger B Nephrol Dial Transplant; 1999 Jan; 14(1):8-11. PubMed ID: 10052462 [No Abstract] [Full Text] [Related]
19. Class II major histocompatibility complex mutant mice to study the germ-line bias of T-cell antigen receptors. Silberman D; Krovi SH; Tuttle KD; Crooks J; Reisdorph R; White J; Gross J; Matsuda JL; Gapin L; Marrack P; Kappler JW Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5608-17. PubMed ID: 27588903 [TBL] [Abstract][Full Text] [Related]
20. Non-canonical peptides bound to MHC. Day SL; Ramsland PA; Apostolopoulos V Curr Pharm Des; 2009; 15(28):3274-82. PubMed ID: 19860676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]